COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,688 Articles (22,478 medRxiv, 8,210 bioRxiv)

Most recent first Previous |  Page 2063: Articles 20621-20630  | Next

Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models
Li, X., Lidsky, P., Xiao, Y., Wu, C.-T., Garcia-Knight, M., Yang, J., Nakayama, T., Nayak, J. V., Jackson, P. K., Andino, R., Shu, X.
10.1101/2020.10.28.359042 — Posted: 2020-10-28
SARS-CoV-2 replication triggers an MDA-5-dependent interferon production which is unable to efficiently control replication
Rebendenne, A., Chaves Valadao, A. L., Tauziet, M., Maarifi, G., Bonaventure, B., Planes, R., McKellar, J., Nisole, S., Arnaud-Arnould, M., Moncorge, O., Goujon, C.
10.1101/2020.10.28.358945 — Posted: 2020-10-28
In vitro assessment of the virucidal activity of four mouthwashes containing Cetylpyridinium Chloride, ethanol, zinc and a mix of enzyme and proteins against a human coronavirus
Green, A., Roberts, G., Tobery, T., Vincent, C., Barili, M., Jones, C.
10.1101/2020.10.28.359257 — Posted: 2020-10-28
5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro
Sakurai, Y., Tun, M. M. N., Kurosaki, Y., Sakura, T., Inaoka, D. K., Fujine, K., Kita, K., Morita, K., Yasuda, J.
10.1101/2020.10.28.355305 — Posted: 2020-10-28
SARS-CoV-2 desensitizes host cells to interferon through inhibition of the JAK-STAT pathway
Chen, D.-Y., Khan, N., Close, B. J., Goel, R. K., Blum, B., Tavares, A. H., Kenney, D., Conway, H. L., Ewoldt, J. K., Kapell, S., Chitalia, V. C., Crossland, N. A., Chen, C. S., Kotton, D. N., Baker, S. C., Connor, J. H., Douam, F., Emili, A., Saeed, M.
10.1101/2020.10.27.358259 — Posted: 2020-10-28
Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-SARS-CoV-2 response in mice.
Polak, K., Greze, N., Lachat, M., Merle, D., Chiumento, S., Bertrand-Gaday, C., Trentin, B., Mamoun, R. Z.
10.1101/2020.10.28.357137 — Posted: 2020-10-28
Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice
Turan, R. D., Tastan, C., Dilek Kancagi, D., Yurtsever, B., Sir Karakus, G., Ozer, S., Abanuz, S., Cakirsoy, D., Tumentemur, G., Demir, S., Seyis, U., Kuzay, R., Elek, M., Ertop, G., Arbak, S., Acikel Elmas, M., Hemsinlioglu, C., Hatirnaz Ng, O., Akyoney, S., Sahin, I., Kayhan, C. K., Tokat, F., Akpinar, G., Kasap, M., Kocagoz, A. S., Ozbek, U., Telci, D., Sahin, F., Yalcin, K., Ratip, S., Ince, U., Suyen, G., Ovali, E.
10.1101/2020.10.28.356667 — Posted: 2020-10-28
Mechanism of SARS-CoV-2 polymerase inhibition by remdesivir
Kokic, G., Hillen, H. S., Tegunov, D., Dienemann, C., Seitz, F., Schmitzova, J., Farnung, L., Siewert, A., Hoebartner, C., Cramer, P.
10.1101/2020.10.28.358481 — Posted: 2020-10-28
Aglycone polyether ionophores as broad-spectrum agents inhibit multiple enveloped viruses including SARS-CoV-2 in vitro and successfully cure JEV infected mice
Liu, T., Li, J.-Q., Huang, M., Zhang, Y.-N., Liu, R., Zhang, Z.-R., Zhang, Q.-Y., Wang, Y., Liu, J., Deng, Z., Zhang, B., Ye, H.-Q.
10.1101/2020.10.27.354563 — Posted: 2020-10-28
A genome-wide CRISPR/Cas9 knock-out screen identifies the DEAD box RNA helicase DDX42 as a broad antiviral inhibitor
Bonaventure, B., Rebendenne, A., Garcia de Gracia, F., Tauziet, M., McKellar, J., Chaves Valadao, A. L., Courgnaud, V., Bernard, E., Briant, L., Gros, N., Djilli, W., Arnaud-Arnould, M., Parrinello, H., Rialle, S., Moncorge, O., Goujon, C.
10.1101/2020.10.28.359356 — Posted: 2020-10-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).